Page last updated: 2024-09-05

lasofoxifene and Spinal Fractures

lasofoxifene has been researched along with Spinal Fractures in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Armstrong, RA; Cummings, SR; Delmas, PD; Eastell, R; Ensrud, K; Goldstein, S; Kendler, D; LaCroix, AZ; Lee, A; Neven, P; Powles, T; Reid, DM; Sriram, U; Thompson, DD; Thompson, J; Vukicevic, S; Zanchetta, J1
Becker, C1
Hadji, P1

Reviews

1 review(s) available for lasofoxifene and Spinal Fractures

ArticleYear
The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Climacteric : the journal of the International Menopause Society, 2012, Volume: 15, Issue:6

    Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Endometrial Neoplasms; Female; Fractures, Bone; Hot Flashes; Humans; Indoles; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Spinal Fractures; Tetrahydronaphthalenes

2012

Trials

1 trial(s) available for lasofoxifene and Spinal Fractures

ArticleYear
Lasofoxifene in postmenopausal women with osteoporosis.
    The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8

    Topics: Aged; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pyrrolidines; Receptors, Estrogen; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tetrahydronaphthalenes; Venous Thromboembolism

2010

Other Studies

1 other study(ies) available for lasofoxifene and Spinal Fractures

ArticleYear
Another selective estrogen-receptor modulator for osteoporosis.
    The New England journal of medicine, 2010, Feb-25, Volume: 362, Issue:8

    Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Coronary Disease; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Pyrrolidines; Raloxifene Hydrochloride; Risk; Selective Estrogen Receptor Modulators; Spinal Fractures; Stroke; Tamoxifen; Tetrahydronaphthalenes; Venous Thromboembolism

2010